Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
VEBrant
Vebreltinib for Advanced or Metastatic CCS
- NCT07153887 ↗
- Recruiting
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Focused
We haven't built an HCP commentary report on VEBrant (vebreltinib in Clear Cell Sarcoma (CCS)) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on VEBrant so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- An Exploratory Clinical Trial of Vebreltinib for the Treatment of Patients With Locally Advanced or Metastatic Clear Cell Sarcoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Clear Cell Sarcoma (CCS)
- Interventions
- Vebreltinib; Standard medical treatment
- Arms
- Vebreltinib Arm · Experimental
- External reference arm · Other
- Enrollment
- 30 (estimated)
- Primary outcomes
- ORR
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Start
- Sep 30, 2025 (estimated)
- Primary completion
- Jul 15, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT07153887 · updated Sep 30, 2025
Publications
linked from the registry- Jiang Y, Lin N, Huang X, Yan X, Liu M, Qu H, Li X, Lin P, Li H, Ye Z, Li B. VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma. Future Oncol. 2026 Jul;22(17):2047-2053. doi: 10.1080/14796694.2026.2695212. Epub 2026 Jun 30. PubMed 42376809